Persistent Asset Partners Ltd Makes New $532,000 Investment in Repligen Corporation $RGEN

Persistent Asset Partners Ltd purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,902 shares of the biotechnology company’s stock, valued at approximately $532,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. United Capital Financial Advisors LLC bought a new stake in Repligen in the third quarter worth $368,387,000. Opti Capital Management LP acquired a new position in Repligen during the fourth quarter worth $2,399,209,000. Maverick Capital Ltd. bought a new position in Repligen during the first quarter valued at about $178,946,000. Wasatch Advisors LP acquired a new stake in shares of Repligen in the first quarter worth about $146,513,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after acquiring an additional 1,091,683 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RGEN. Canaccord Genuity Group lowered their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. HSBC reduced their target price on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Barclays upped their target price on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Evercore reissued an “outperform” rating and issued a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Repligen presently has a consensus rating of “Buy” and a consensus target price of $166.43.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $166.83 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The stock’s 50-day moving average is $142.70 and its 200-day moving average is $131.10. The company has a market cap of $9.42 billion, a P/E ratio of 228.53, a P/E/G ratio of 3.04 and a beta of 1.03. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter in the previous year, the firm earned $0.26 EPS. The firm’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.